The Asia Pacific Dementia Treatment Market would witness market growth of 8.0% CAGR during the forecast period (2024-2031).
The China market dominated the Asia Pacific Dementia Treatment Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of$2.13 billion by 2031. The Japan market is registering a CAGR of 7.3% during (2024 - 2031). Additionally, The India market would capture a CAGR of 8.7% during (2024 - 2031).
The increasing investment in healthcare infrastructure globally is facilitating the growth of the dementia treatment market. In order to accommodate the increasing number of dementia patients, governments and private entities are making investments in the construction as well as modernization of healthcare facilities. This encompasses the establishment of innovative diagnostic tools and therapeutic modalities in specialized memory clinics and dementia care centers. Such investments are crucial in enhancing the early detection and management of dementia, improving patient outcomes and quality of life.
Pharmacological treatments remain a cornerstone of dementia management, with ongoing research focused on developing new and more effective medications. Current treatments primarily aim to manage symptoms and improve cognitive function. Cholinesterase inhibitors, such as donepezil, rivastigmine, and galantamine, are commonly prescribed to improve cognitive symptoms in mild to moderate Alzheimer’s disease. NMDA receptor antagonists, like memantine, treat moderate to severe cases.
In India, the demand for dementia treatment is growing due to the increasing prevalence of dementia and the country’s aging population. According to the National Library of Medicine, approximately 8.8 million people in India were living with dementia in 2023, a number expected to increase significantly in the coming decades. The Indian government has been working to improve dementia care through initiatives like the National Programme for Health Care of the Elderly (NPHCE), which includes provisions for dementia care and support. Increased awareness, early diagnosis efforts, and investments in healthcare infrastructure drive the demand for dementia treatments in India. Therefore, the demand for dementia treatments will rise significantly in this region in the coming years.
Based on Type, the market is segmented into Diagnosis (Imaging Techniques, Cognitive Assessment Tools, Genetic Testing, Biomarker Analysis and Others) and Drugs (Cholinesterase Inhibitors, NMDA Receptor Antagonist, MAO Inhibitors, Combination Drug and Others). Based on Dementia Drugs Route of Administration, the market is segmented into Oral, Transdermal Patch, and Injectable. Based on Dementia Drugs Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy. Based on Indication, the market is segmented into Alzheimer’s Disease Dementia, Vascular Dementia, Lewy Body Dementia, Frontotemporal Dementia (FTD), Parkinson Disease Dementia and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The China market dominated the Asia Pacific Dementia Treatment Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of$2.13 billion by 2031. The Japan market is registering a CAGR of 7.3% during (2024 - 2031). Additionally, The India market would capture a CAGR of 8.7% during (2024 - 2031).
The increasing investment in healthcare infrastructure globally is facilitating the growth of the dementia treatment market. In order to accommodate the increasing number of dementia patients, governments and private entities are making investments in the construction as well as modernization of healthcare facilities. This encompasses the establishment of innovative diagnostic tools and therapeutic modalities in specialized memory clinics and dementia care centers. Such investments are crucial in enhancing the early detection and management of dementia, improving patient outcomes and quality of life.
Pharmacological treatments remain a cornerstone of dementia management, with ongoing research focused on developing new and more effective medications. Current treatments primarily aim to manage symptoms and improve cognitive function. Cholinesterase inhibitors, such as donepezil, rivastigmine, and galantamine, are commonly prescribed to improve cognitive symptoms in mild to moderate Alzheimer’s disease. NMDA receptor antagonists, like memantine, treat moderate to severe cases.
In India, the demand for dementia treatment is growing due to the increasing prevalence of dementia and the country’s aging population. According to the National Library of Medicine, approximately 8.8 million people in India were living with dementia in 2023, a number expected to increase significantly in the coming decades. The Indian government has been working to improve dementia care through initiatives like the National Programme for Health Care of the Elderly (NPHCE), which includes provisions for dementia care and support. Increased awareness, early diagnosis efforts, and investments in healthcare infrastructure drive the demand for dementia treatments in India. Therefore, the demand for dementia treatments will rise significantly in this region in the coming years.
Based on Type, the market is segmented into Diagnosis (Imaging Techniques, Cognitive Assessment Tools, Genetic Testing, Biomarker Analysis and Others) and Drugs (Cholinesterase Inhibitors, NMDA Receptor Antagonist, MAO Inhibitors, Combination Drug and Others). Based on Dementia Drugs Route of Administration, the market is segmented into Oral, Transdermal Patch, and Injectable. Based on Dementia Drugs Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy. Based on Indication, the market is segmented into Alzheimer’s Disease Dementia, Vascular Dementia, Lewy Body Dementia, Frontotemporal Dementia (FTD), Parkinson Disease Dementia and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
List of Key Companies Profiled
- Eisai Co., Ltd.
- Eli Lilly And Company
- F.Hoffmann-La Roche Ltd.
- Biogen, Inc.
- AbbVie, Inc.
- Novartis AG
- Sun Pharmaceutical Industries Ltd.
- Takeda Pharmaceutical Company Limited
- GlaxoSmithKline PLC (GSK)
- Cipla Limited
Market Report Segmentation
By Type- Diagnosis
- Imaging Techniques
- Cognitive Assessment Tools
- Genetic Testing
- Biomarker Analysis
- Others
- Drugs
- Cholinesterase Inhibitors
- NMDA Receptor Antagonist
- MAO Inhibitors
- Combination Drug
- Others
- Oral
- Transdermal Patch
- Injectable
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Alzheimer’s Disease Dementia
- Vascular Dementia
- Lewy Body Dementia
- Frontotemporal Dementia (FTD)
- Parkinson Disease Dementia
- Others
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. Asia Pacific Dementia Treatment Market by Type
Chapter 5. Asia Pacific Dementia Treatment Market by Dementia Drugs Route of Administration
Chapter 6. Asia Pacific Dementia Treatment Market by Dementia Drugs Distribution Channel
Chapter 7. Asia Pacific Dementia Treatment Market by Indication
Chapter 8. Asia Pacific Dementia Treatment Market by Country
Chapter 9. Company Profiles
Companies Mentioned
- Eisai Co., Ltd.
- Eli Lilly And Company
- F. Hoffmann-La Roche Ltd.
- Biogen, Inc.
- AbbVie, Inc.
- Novartis AG
- Sun Pharmaceutical Industries Ltd.
- Takeda Pharmaceutical Company Limited
- GlaxoSmithKline PLC (GSK)
- Cipla Limited
Methodology
LOADING...
